Thomas A. Macek
International Society for Infectious Diseases(US)Inotek Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Neurogenetic and Muscular Disorders Research, Bipolar Disorder and Treatment, Schizophrenia research and treatment, Receptor Mechanisms and Signaling, RNA modifications and cancer
Most-Cited Works
- → Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial(2021)456 cited
- → Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial(2022)275 cited
- → Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial(2022)260 cited
- → A 3‐week, randomized, placebo‐controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states(2009)188 cited
- → Differential involvement of group II and group III mGluRs as autoreceptors at lateral and medial perforant path synapses(1996)182 cited
- → Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial(2010)160 cited